Plasma Protease C1-inhibitor Treatment Market on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
Plasma Protease C1-inhibitor Treatment Market contains market size and forecasts of Plasma Protease C1-inhibitor Treatment in Global, including the following market information:
- Global Plasma Protease C1-inhibitor Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Plasma Protease C1-inhibitor Treatment market was valued at 3265.3 million in 2021 and is projected to reach US$ 9559.1 million by 2028, at a CAGR of 16.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
C1-inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Plasma Protease C1-inhibitor Treatment include Takeda, CSL, Sanquin and Pharming Group, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Plasma Protease C1-inhibitor Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Plasma Protease C1-inhibitor Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Plasma Protease C1-inhibitor Treatment Market Segment Percentages, by Type, 2021 (%)
- C1-inhibitors
- Kallikrein Inhibitor (Kalbitor)
Global Plasma Protease C1-inhibitor Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Plasma Protease C1-inhibitor Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospital Pharmacies
- Independent Pharmacies and Outlets
Global Plasma Protease C1-inhibitor Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Plasma Protease C1-inhibitor Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Plasma Protease C1-inhibitor Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Plasma Protease C1-inhibitor Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Takeda
- CSL
- Sanquin
- Pharming Group
Industry Market Size
